Ala. pharmacist appointed NCPA president for 2012-13
ALEXANDRIA, Va. — The National Community Pharmacists Association has a new crop of leaders for 2012-13, the group said Wednesday.
The new officers and board of directors, announced at the NCPA’s 114th Annual Convention and Trade Exposition, are the group’s governing body.
Anniston, Ala., pharmacy owner Donnie Calhoun was named NCPA president; he serves on the NCPA’s board of directors and is a national director for Pharmacist’s Mutual Insurance Company. He is also the 2012 president of the Alabama Board of Pharmacy, having previously served on the board of directors of the National Home Infusion Association and the Alabama Pharmacy Association.
"We congratulate Donnie Calhoun on becoming NCPA president," NCPA CEO B. Douglas Hoey said. "Whether at the local, state or federal level, Donnie has been an effective advocate for independent community pharmacists and the patients they serve."
In addition to Calhoun, the board of directors includes president-elect Mark Riley, Little Rock, Ark.; chairman Bradley Arthur, Buffalo, N.Y.; immediate past president Lonny Wilson, Oklahoma City; board member John Sherrer, Marietta, Ga.; Keith Hodges, Gloucester, Va.; DeAnn Mullins, Lynn Haven, Fla.; David Smith, Indiana, Pa.; and Bill Osborn, Miami, Okla.
The officers are first VP Brian Caswell, Baxter Springs, Kan.; second VP Michele Belcher, Grants Pass, Ore.; third VP Hugh Chancy, Hahira, Ga.; fourth VP Jeff Carson, San Antonio; and fifth VP Lea Wolsoncroft, Birmingham, Ala.
Wolsoncroft is the newest member to join the roster of pharmacy leaders for the NCPA and is the founder of Kids Meds Pharmacy, which specializes in drugs for children, the NCPA said.
Mylan hopes to stop Watson launch of diabetes drug
PITTSBURGH — Mylan is challenging a federal court decision ordering the Food and Drug Administration to allow Watson Pharmaceuticals to launch a generic diabetes drug, Mylan said.
The generic drug maker said it filed a motion in the U.S. District Court for the District of Columbia Tuesday to stay the court’s order, which called on the FDA to let Watson launch a generic version of Takeda’s Type 2 diabetes drug Actos (pioglitazone).
"Mylan is disappointed in yesterday’s ruling regarding pioglitazone, and we believe the court erred in its decision by directly contravening the Hatch-Waxman Act," Mylan CEO Heather Bresch said, referring to the 1984 law that created an abbreviated approval pathway for generic pharmaceutical drugs. "Mylan does not believe Watson is entitled to participate in Mylan’s 180-day exclusivity period in relation to this product, and we intend to pursue this case vigorously, including seeking expedited relief from the appellate court if necessary."
Watson filed suit against the FDA in August 2012, alleging that an agency decision to deny Watson’s claim to shared exclusivity in marketing a generic version of Actos would improperly delay its launch of the drug.
Actos had sales of about $2.7 billion during the 12-month period ended in May, according to IMS Health.
Catamaran gets $60 million in contracts from Indiana Medicaid program
LISLE, Ill. — Pharmacy benefit manager Catamaran has won contracts with Indiana’s state Medicaid program, the company said.
Catamaran said it was awarded the contracts, worth $60 million, to provide implementation, adjudication and PBM services to the program for six years, not including two one-year options. Catamaran will provide what it called a flexible and customized suite of PBM services, including implementation, claims processing, clinical and technical call center services, electronic prescribing, federal and supplemental rebate administration, pharmacy audits, specialty medication management and "enhanced" coordination of benefits, among others. The services will start on April 1, 2013.
"Catamaran is building incredible momentum around creating tailored, innovative PBM solutions for state governments seeking to reduce healthcare costs, simplify the delivery of medicine and improve the health of their beneficiaries," Catamaran chairman and CEO Mark Thierer said. "As a consultative partner to the state of Indiana, Catamaran will provide services and technology solutions to streamline the program and avoid the costly events that the right medicine or intervention can deter."